Datapoint: Amgen Suffers Another Repatha Patent Setback

The U.S. Court of Appeals for the Federal Circuit last week declined to hear Amgen’s appeal to reconsider a key patent loss for its PCSK9 drug Repatha. This is just the latest chapter in a saga that dates back to 2014, when Amgen sued Sanofi and Regeneron to protect Repatha’s patents against the competing Praluent. The legal battle ultimately delayed Praluent’s launch. Amgen can still press its appeal further, but it’s unclear what the drugmaker will decide to do. Under the pharmacy benefit, Repatha holds covered or better status for 77% of all insured lives, to Praluent’s 71%.

SOURCE: MMIT Analytics, as of 6/23/21

0

0

0 Comments

0

0

• Datapoint